Target intelligence / Profile preview

Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1)

Target
PLOD1
Molecular classification
Enzyme, Alpha-ketoglutarate-dependent hydroxylase, Dioxygenase
01

Overview

Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) is an essential enzyme involved in the hydroxylation of lysine residues in collagen and related proteins, a key post-translational modification required for stable intermolecular cross-linking and maturation of connective tissue structures[1][2][3][6]. PLOD1 is a membrane-bound homodimer primarily localized to the endoplasmic reticulum, requiring iron and ascorbate (vitamin C) cofactors for enzymatic activity[3][6]. Deficiency or mutations in PLOD1 result in decreased hydroxylysine formation, unstable collagen cross-linking, and manifestations of genetic diseases such as kyphoscoliotic type Ehlers-Danlos syndrome and familial thoracic aortic aneurysm/dissection[1][2][5]. Emerging research indicates that PLOD1 may participate in the regulation of actin cytoskeletal networks and support cancer cell migration and metastasis, notably in hepatocellular carcinoma[4]. Recent mechanistic insights also suggest minor glycosyltransferase activity by PLOD1, with potential impacts on extracellular matrix composition, though this function is considerably lower compared to homologous enzymes[5]. There are currently no known approved drugs directly targeting PLOD1, and therapeutic modulation carries notable risks due to its fundamental role in tissue stability.

Other names
Lysyl hydroxylase 1LH1Procollagen lysyl hydroxylase 1Lysine hydroxylaseEDS6EDSKCL1LLHLHPLOD
02

Biological functions

Hydroxylation of lysine residues in collagenCollagen post-translational modificationStabilization of collagen cross-linksExtracellular matrix organizationGlycosyltransferase activity (minor; possible per recent findings)
03

Disease associations

Ehlers-Danlos syndrome, kyphoscoliotic type (EDS VI)Familial thoracic aortic aneurysm/dissectionHepatocellular carcinoma (metastasis and migration)Other connective tissue disorders
04

Safety considerations

Targeting could disrupt normal collagen formation and connective tissue integrity, risking tissue weakness or instabilityRarity and complexity of disease mechanisms in connective tissue and aortic disorders complicate therapeutic intervention
05

Biomarkers

PLOD1 gene mutation for diagnosis of kyphoscoliotic Ehlers-Danlos syndromePentosidine (marker for collagen turnover, referenced in FTAAD study)

Beyond the preview

Go deeper on Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call